Evaluation criteria for vaccines for endemic disease prevention through routine immunisation

	Criteria	Indicators
Ranking criteria:	Health impact	Total future deaths averted in the 2020-2035 period, and per 100,000 vaccinated Total future cases averted in the 2020-2035 period, and per 100,000 vaccinated
	Value for money	Vaccine procurement cost per death averted Vaccine procurement cost per case averted
	Equity and social protection impact	Disproportionate impact of disease on vulnerable groups Special benefits of vaccination for women and girls
	Economic impact	Direct medical costs averted Indirect costs averted
	Global health security impact	Epidemic potential of disease Impact of vaccination on antimicrobial resistance (AMR)
Secondary criteria:	Other impact	Total under-five deaths averted in the 2020-2035 period, and per 100,000 vaccinated Total DALYs averted in the 2020-2035 period, and per 100,000 vaccinated Vaccine procurement cost per disability-adjusted life year (DALY) averted
	Gavi comparative advantage	Degree of vaccine market challenges Potential for Gavi support to catalyse additional investment
	Implementation feasibility	Ease of supply chain integration Need for healthcare worker behaviour change Feasibility of vaccination time point Acceptability in target population Long-term financial implications
	Alternative interventions	Optimal use of current and future alternative interventions (prevention and treatment)
	Broader health system benefits	No specific indicator – evaluated on a case-by-case basis
Financial implications:	Vaccine cost	Total procurement cost to Gavi and countries, 2020-2035
	Operational cost	Incremental in-country operational costs per vaccinated person
	Additional implementation costs	Additional costs for introduction

Last updated: 10 Nov 2019

Subscribe to our newsletter